课题基金 / 基金详情

MOLECULAR IMMUNE RESPONSE DETERMINANTS OF RUBELLA VIRUS

MOLECULAR IMMUNE RESPONSE DETERMINANTS OF RUBELLA VIRUS
风疹病毒的分子免疫反应决定因素
批准号:
3141046
负责人:
Jerry Saul Wolinsky
金额:
$19.0万
依托单位国家:
美国
项目类别:
财政年份:
1989
资助国家:
美国
项目状态:
已结题
起止时间:
1989-06-01 至 1994-05-31

项目摘要

项目成果

Jerry Saul Wolinsky的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Our ultimate goal is to determine how aberrant immune responses to rubella virus contribute to the clinical and pathological manifestations of the congenital rubella syndrome, progressive rubella panencephalitis, vaccine arthralgia and perhaps rheumatoid arthritis and multiple sclerosis. A prerequisite is the construction of the molecular topography of the antigenic domains of rubella virus which elicit humoral and cell-mediated immune responses. This will provide the required data base to define the predicted alterations in the human immune response which contribute to the diverse complications of rubella. This project will define the minimum domains of rubella virus that are required to induce antibody responses which interrupt virus infectivity, and those amino acid sequences of the structural proteins which are processed and presented by human monocytes to establish cellular immunity. A library of monoclonal antibodies to rubella virus will be expanded and used to define both sequential and conformation- dependant antigen bearing domains residing on the structural polypeptides. These experiments will utilize novel approaches which combine the power of immunoprecipitation, antibody protected partial proteolytic digestion, SDS-PAGE and fast atom bombardment mass spectrometry. In vitro proliferative assays which use polypeptides or their fragments bound to particulate nitrocellulose will define antigenic domains recognized by immune cells. Selected synthetic oligopeptides will confirm the importance of these domains and provide reagents with which to probe critical differences between normal and anomalous responses in rubella related syndromes. The knowledge gained will increase our understanding of normal immune responses to this common human pathogen, provide critical information of use in constructing molecularly engineered vaccines, facilitate the approach of others to this general problem, and provide better insight into aberrant human immune responses and their contribution to viral persistence and virus-induced immunopathology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
COPAXONE IN PATIENTS WITH MULTIPLE SCLEROSIS--OPEN LABEL STUDY
海外基金